Fairvalue-Calculator Fairvalue-Calculator
EN DE

Crescent Capital BDC, Inc (CCAP) Fair Value & Analysis

Financial Services · US · Market cap $412M

Price$10.96
Fair Value$15.92
Upside+45.3%
Quality95/100
Evidence: High Range $11.94 – $19.90

Fair value as of: Jun 26, 2026

Analysis

Crescent Capital BDC, Inc (CCAP) currently trades at $10.96, while our model-based Fair Value estimate is $15.92 — implying the stock looks roughly 45.3% undervalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Crescent Capital BDC, Inc. is as a business development company is a private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Crescent Capital BDC, Inc (CCAP) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $15.92 versus a price of $10.96 — about +45% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CCAP?
Our 21-model fair value for Crescent Capital BDC, Inc is $15.92 (as of Jun 26, 2026), built from audited fundamentals. The current price is $10.96.
What is the quality score of CCAP?
Crescent Capital BDC, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.